Minimum Inhibitory Concentration Breakpoints and Disk Diffusion Inhibitory Zone Interpretive Criteria for Tilmicosin Susceptibility Testing against Pasteurella Multocida and Actinobacillus Pleuropneumoniae Associated with Porcine Respiratory Disease

Abstract

Tilmicosin is a novel macrolide antibiotic developed for exclusive use in veterinary medicine. Tilmicosin has been approved as a feed premix to control porcine respiratory disease associated with Pasteurella multocida and Actinobacillus pleuropneumoniae. The development of antimicrobial susceptibility testing guidelines for tilmicosin was predicated on the relationship of clinical efficacy studies that demonstrated a favorable therapeutic outcome, on pharmacokinetic data, and on in vitro test data, as recommended by the National Committee for Clinical Laboratory Standards (NCCLS). The approved breakpoints for the minimum inhibitory concentration dilution testing for both species are resistant, ≥32 μg/ml, and susceptible, ≤16 μg/ml. The zone of inhibition interpretive criteria for disk diffusion testing with a 15-μg tilmicosin disk are resistant, ≤10 mm, and susceptible, ≥11mm.